Malcolm Salter - 04 Jan 2022 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Director
Signature
/s/ Jolie M. Siegel, Attorney-in-Fact
Issuer symbol
CCCC
Transactions as of
04 Jan 2022
Net transactions value
+$13,516
Form type
4
Filing time
18 Jan 2022, 15:30:40 UTC
Previous filing
17 Dec 2021
Next filing
23 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Award $13,516 +428 +3.9% $31.58* 11,380 04 Jan 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
F2 The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 4, 2022.